De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
Ovidio De FilippoFrancesco PiroliFrancesco BrunoPier Paolo BocchinoAndrea SagliettoLuca FranchinFilippo AngeliniGuglielmo GalloneGiulia RizzelloMahmood AhmadMauro GaspariniSaurav ChatterjeeGaetano Maria De FerrariFabrizio D'AscenzoPublished in: BMJ evidence-based medicine (2024)
DAPT de-escalation and ASA-clopidogrel regimens may reduce bleeding events compared with 12 months ASA and potent P2Y12 inhibitors. 3-6 months or 12-month aspirin-clopidogrel may increase ST risk compared with 12-month aspirin plus potent P2Y12 inhibitors, while DAPT de-escalation probably does not.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- open label
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- coronary artery bypass
- clinical trial
- type diabetes
- randomized controlled trial
- heart failure
- left ventricular
- study protocol